429 related articles for article (PubMed ID: 32428864)
21. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
22. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
Ni W; Yang X; Yang D; Bao J; Li R; Xiao Y; Hou C; Wang H; Liu J; Yang D; Xu Y; Cao Z; Gao Z
Crit Care; 2020 Jul; 24(1):422. PubMed ID: 32660650
[TBL] [Abstract][Full Text] [Related]
23. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
24. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Li SR; Tang ZJ; Li ZH; Liu X
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
[TBL] [Abstract][Full Text] [Related]
25. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
Dabaghian F; Khanavi M; Zarshenas MM
Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
[No Abstract] [Full Text] [Related]
26. The therapeutic potential of targeting ACE2 in COVID-19.
Elmorsi R
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9744-9747. PubMed ID: 33015820
[TBL] [Abstract][Full Text] [Related]
27. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
[No Abstract] [Full Text] [Related]
28. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
29. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
30. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
31. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
32. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells.
Stelzig KE; Canepa-Escaro F; Schiliro M; Berdnikovs S; Prakash YS; Chiarella SE
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1280-L1281. PubMed ID: 32432918
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
34. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?
Silhol F; Sarlon G; Deharo JC; Vaïsse B
Hypertens Res; 2020 Aug; 43(8):854-856. PubMed ID: 32439915
[No Abstract] [Full Text] [Related]
36. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
37. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.
Rehman SU; Tabish M
Clin Sci (Lond); 2020 May; 134(10):1143-1150. PubMed ID: 32442315
[TBL] [Abstract][Full Text] [Related]
38. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
40. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]